CA2701198A1 - Procedes sensibles et rapides d'utilisation de recepteurs chimeriques pour identifier une maladie auto-immune - Google Patents

Procedes sensibles et rapides d'utilisation de recepteurs chimeriques pour identifier une maladie auto-immune Download PDF

Info

Publication number
CA2701198A1
CA2701198A1 CA2701198A CA2701198A CA2701198A1 CA 2701198 A1 CA2701198 A1 CA 2701198A1 CA 2701198 A CA2701198 A CA 2701198A CA 2701198 A CA2701198 A CA 2701198A CA 2701198 A1 CA2701198 A1 CA 2701198A1
Authority
CA
Canada
Prior art keywords
cells
cho
tsh
cell
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2701198A
Other languages
English (en)
Other versions
CA2701198C (fr
Inventor
James L. Brown
Leonard Kohn
David Scholl
Yunsheng Li
Giorgio Napolitano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnostic Hybrids Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/906,189 external-priority patent/US8293879B2/en
Application filed by Individual filed Critical Individual
Publication of CA2701198A1 publication Critical patent/CA2701198A1/fr
Application granted granted Critical
Publication of CA2701198C publication Critical patent/CA2701198C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/046—Thyroid disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La présente invention concerne des procédés et des compostions utiles dans le diagnostic et la gestion de maladies auto-immunes. En particulier, la présente invention concerne des procédés et des compositions améliorés pour le diagnostic et la gestion de la maladie de Graves. Les procédés selon la présente invention éliminent non seulement le recours à la radioactivité et sont beaucoup plus simples, économiques, et rapides que les procédés utilisés traditionnellement pour le diagnostic de la maladie de Graves, mais améliorent également les capacités de sensibilité et de détection des dosages pour la détection d'anticorps précédents basée sur la luciférase. De telles améliorations sont basées sur l'efficacité supérieure de dosages comportant un récepteur chimérique TSH en présence d'un glucocorticoïde comprenant, entre autres, le dexaméthasone.
CA2701198A 2007-10-01 2008-09-24 Procedes sensibles et rapides d'utilisation de recepteurs chimeriques pour identifier une maladie auto-immune Active CA2701198C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/906,189 2007-10-01
US11/906,189 US8293879B2 (en) 2000-03-30 2007-10-01 Methods of using chimeric receptors to identify autoimmune disease
US20632208A 2008-09-08 2008-09-08
US12/206,322 2008-09-08
PCT/US2008/011027 WO2009045292A1 (fr) 2007-10-01 2008-09-24 Procédés sensibles et rapides d'utilisation de récepteurs chimériques pour identifier une maladie auto-immune

Publications (2)

Publication Number Publication Date
CA2701198A1 true CA2701198A1 (fr) 2009-04-09
CA2701198C CA2701198C (fr) 2015-07-21

Family

ID=40526500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2701198A Active CA2701198C (fr) 2007-10-01 2008-09-24 Procedes sensibles et rapides d'utilisation de recepteurs chimeriques pour identifier une maladie auto-immune

Country Status (7)

Country Link
EP (1) EP2201130A4 (fr)
JP (1) JP5474802B2 (fr)
KR (1) KR101560849B1 (fr)
CN (1) CN101918585A (fr)
AU (1) AU2008307735B2 (fr)
CA (1) CA2701198C (fr)
WO (1) WO2009045292A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2765558C (fr) * 2009-06-30 2018-09-25 Otsuka Pharmaceutical Co., Ltd. Procede de biodosage d'anticorps anti-recepteurs de la thyreostimuline, necessaire de dosage desdits anticorps et cellule inedite genetiquement modifiee utilisable dans le cadre dudit biodosage ou avec ledit necessaire de dosage
JP7211596B2 (ja) * 2018-09-05 2023-01-24 ヤマサ醤油株式会社 Ｔｓｈ受容体に対する自己抗体活性の測定方法及びキット

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720693D0 (en) * 1997-09-30 1997-11-26 Univ Wales Medicine Assay
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
US6852546B1 (en) * 2000-03-30 2005-02-08 Diagnostic Hybrids, Inc. Diagnosis of autoimmune disease
US7998681B2 (en) * 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
US6901485B2 (en) * 2001-06-21 2005-05-31 International Business Machines Corporation Memory directory management in a multi-node computer system

Also Published As

Publication number Publication date
JP2010539975A (ja) 2010-12-24
KR101560849B1 (ko) 2015-11-20
AU2008307735B2 (en) 2014-04-24
AU2008307735A1 (en) 2009-04-09
CA2701198C (fr) 2015-07-21
EP2201130A4 (fr) 2010-10-06
CN101918585A (zh) 2010-12-15
KR20100101072A (ko) 2010-09-16
EP2201130A1 (fr) 2010-06-30
WO2009045292A1 (fr) 2009-04-09
JP5474802B2 (ja) 2014-04-16

Similar Documents

Publication Publication Date Title
US10564159B2 (en) Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
US10041943B2 (en) Methods of using chimeric receptors to identify autoimmune disease
US20240133882A1 (en) Compositions and methods for detecting autoantibodies
TW201802472A (zh) 抗人類血紅素單株抗體或抗體套組、抗人類血紅素單株抗體固定化不可溶性載體粒子、及使用其等之測定試劑或測定方法
CA2701198C (fr) Procedes sensibles et rapides d'utilisation de recepteurs chimeriques pour identifier une maladie auto-immune
CA2404502C (fr) Diagnostic de maladies autoimmunes par la detection d'anticorps stimulant la thyroide
CN114720691B (zh) 一种检测生物标志物的试剂盒及其制备方法和应用
AU2001249620A1 (en) Diagnosis of autoimmune disease
CN104650245B (zh) 一种融合的叶酸结合蛋白质、基因序列及试剂盒
US20130109107A1 (en) Diagnosis and treatment of autoimmune disease
JPWO2002052032A1 (ja) 標的細胞の細胞死の測定方法
JP2000197483A (ja) ＲｅｃＱＤＮＡヘリカ―ゼファミリ―遺伝子の変異に起因する疾患の検査方法

Legal Events

Date Code Title Description
EEER Examination request